DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma.

Ishiguro K, Kitajima H, Niinuma T, Maruyama R, Tsukahara T, Hirohashi Y, Takaya A, Kumegawa K, Yoshido A, Sekiguchi S, Sasaki H, Yorozu A, Toyota M, Kai M, Torigoe T, Nakase H, Suzuki H

Open source

DOI: 10.1016/j.canlet.2025.217941
Published: 2025 Oct 28
Container: Cancer letters
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.canlet.2025.217941,
  title = {DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma.},
  author = {Ishiguro K and Kitajima H and Niinuma T and Maruyama R and Tsukahara T and Hirohashi Y and Takaya A and Kumegawa K and Yoshido A and Sekiguchi S and Sasaki H and Yorozu A and Toyota M and Kai M and Torigoe T and Nakase H and Suzuki H},
  year = {2025},
  journal = {Cancer letters},
  doi = {10.1016/j.canlet.2025.217941},
  url = {https://doi.org/10.1016/j.canlet.2025.217941}
}

RIS

TY  - JOUR
TI  - DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma.
AU  - Ishiguro K
AU  - Kitajima H
AU  - Niinuma T
AU  - Maruyama R
AU  - Tsukahara T
AU  - Hirohashi Y
AU  - Takaya A
AU  - Kumegawa K
AU  - Yoshido A
AU  - Sekiguchi S
AU  - Sasaki H
AU  - Yorozu A
AU  - Toyota M
AU  - Kai M
AU  - Torigoe T
AU  - Nakase H
AU  - Suzuki H
PY  - 2025
JO  - Cancer letters
DO  - 10.1016/j.canlet.2025.217941
UR  - https://doi.org/10.1016/j.canlet.2025.217941
ER  -

APA

K, I., H, K., T, N., R, M., T, T., Y, H., A, T., K, K., A, Y., S, S., H, S., A, Y., M, T., M, K., T, T., H, N., & H, S. (2025). DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma.. Cancer letters. https://doi.org/10.1016/j.canlet.2025.217941

Source records

pubmed · retrieved 2026-09-25T20:22:58.212Z